Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous ipsc-derived rpe
- Development stage
- Phase 1
- Lead developer
- National Eye Institute
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Subretinal
01
Overview
Autologous iPSC-derived RPE is a cell therapy designed to treat geographic atrophy (GA) associated with age-related macular degeneration (AMD). This therapeutic approach involves generating induced pluripotent stem cells (iPSCs) from a patient's own somatic cells, differentiating these iPSCs into retinal pigment epithelium (RPE) cells, and subsequently transplanting these autologous RPE cells into the subretinal space of the same patient. The primary objective is to replace degenerated RPE cells, thereby aiming to rescue the overlying neurosensory retina from further degeneration. In some clinical applications, the RPE cells are grown as a monolayer on a biodegradable poly lactic-co-glycolic acid (PLGA) scaffold prior to transplantation. Immunosuppressive medications are also administered to mitigate the risk of transplant rejection.
- Other names
- autologous iPSC-derived RPEautologous iRPE patchautologous induced pluripotent stem cell-derived RPE
Beyond the preview
Go deeper on autologous ipsc-derived rpe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous ipsc-derived rpe.